Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1UD
|
|||
| Former ID |
DIB014761
|
|||
| Drug Name |
STI-001
|
|||
| Synonyms |
AP4-24H11; STI-001 program (mAbs targeting S aureus auto-inducing peptides); Fully human anti-AIP monoclonal antibody (MRSA/bacterial infections), Sorrento Therapeutics; Quorum sensing-targeting antibodies (MRSA/bacterial infections), Sorrento Therapeutics; STI-001 program (mAbs targeting S aureus auto-inducing peptides), Sorrento Therapeutics
Click to Show/Hide
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [1] | |
| Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Investigative | [2] | ||
| Company |
Sorrento Therapeutics Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.